340 related articles for article (PubMed ID: 23420592)
21. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
Tojo K; Sakai S; Miyahara T
Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1153-60. PubMed ID: 3216557
[No Abstract] [Full Text] [Related]
22. Therapeutic apheresis in kidney diseases: an updated review.
Chen YY; Sun X; Huang W; He FF; Zhang C
Ren Fail; 2022 Dec; 44(1):842-857. PubMed ID: 35723077
[TBL] [Abstract][Full Text] [Related]
23. Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.
Dittrich-Riediger J; Schatz U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():45-52. PubMed ID: 25936304
[TBL] [Abstract][Full Text] [Related]
24. [The extracorporeal elimination of LDL cholesterol by apheresis. The indications and methods].
Olbricht CJ
Dtsch Med Wochenschr; 1991 Apr; 116(16):625-30. PubMed ID: 2015780
[No Abstract] [Full Text] [Related]
25. Optimization of therapeutic procedure during LDL-apheresis - verification of the computerized model in clinical practice.
Masin V; Blaha M; Stransky P; Blaha V; Cermanova M; Maly R; Zajic J
Transfus Apher Sci; 2007 Feb; 36(1):39-45. PubMed ID: 17292673
[TBL] [Abstract][Full Text] [Related]
26. A case report of the cascade filtration system: a safe and effective method for low-density lipoprotein apheresis during pregnancy.
Ertorer ME; Guvenc B; Haydardedeoglu B; Tekinturhan F
Ther Apher Dial; 2008 Oct; 12(5):396-400. PubMed ID: 18937724
[TBL] [Abstract][Full Text] [Related]
27. The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection.
Ahmed T; Senzel L
J Clin Apher; 2012; 27(4):173-7. PubMed ID: 22411078
[TBL] [Abstract][Full Text] [Related]
28. Technical and clinical experience with protein A immunoadsorption columns.
Belàk M; Borberg H; Jimenez C; Oette K
Transfus Sci; 1994 Dec; 15(4):419-22. PubMed ID: 10155559
[TBL] [Abstract][Full Text] [Related]
29. Application of LDL-apheresis and immunoadsorption in kidney diseases.
Sułowicz W; Stompór T
Rocz Akad Med Bialymst; 2004; 49():127-34. PubMed ID: 15631328
[TBL] [Abstract][Full Text] [Related]
30. Protein adsorption during LDL-apheresis: proteomic analysis.
Dihazi H; Koziolek MJ; Söllner T; Kahler E; Klingel R; Neuhoff R; Strutz F; Mueller GA
Nephrol Dial Transplant; 2008 Sep; 23(9):2925-35. PubMed ID: 18398017
[TBL] [Abstract][Full Text] [Related]
31. Comparison of different low density lipoprotein apheresis machines on brain natriuretic Peptide levels in patients with familial hypercholesterolemia.
Moriarty P; Sosland R; Gibson C; Belmont J
Ther Apher Dial; 2010 Feb; 14(1):74-8. PubMed ID: 20438521
[TBL] [Abstract][Full Text] [Related]
32. Characterization of Fractionation Membranes in an Animal Model of Double Filtration Lipoprotein Apheresis.
Krieter DH; Lange F; Lemke HD; Bonn F; Wanner C
Ther Apher Dial; 2018 Apr; 22(2):189-195. PubMed ID: 29316258
[TBL] [Abstract][Full Text] [Related]
33. [Immunomodulation with apheresis technics].
Liebert A; Quietzsch D; Zimmermann S
Allerg Immunol (Leipz); 1986; 32(1):5-18. PubMed ID: 2940851
[TBL] [Abstract][Full Text] [Related]
34. Low-density lipoprotein apheresis using the Liposorber dextran sulfate cellulose system for patients with hypercholesterolemia refractory to medical therapy.
Gordon BR; Saal SD
J Clin Apher; 1996; 11(3):128-31. PubMed ID: 8915816
[TBL] [Abstract][Full Text] [Related]
35. Lipid reductions by low-density lipoprotein apheresis: a comparison of three systems.
Jovin IS; Taborski U; Stehr A; Müller-Berghaus G
Metabolism; 2000 Nov; 49(11):1431-3. PubMed ID: 11092506
[TBL] [Abstract][Full Text] [Related]
36. Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products. British Committee for Standards in Haematology.
Howell C; Douglas K; Cho G; El-Ghariani K; Taylor P; Potok D; Rintala T; Watkins S
Transfus Med; 2015 Apr; 25(2):57-78. PubMed ID: 26013470
[No Abstract] [Full Text] [Related]
37. Is lipoprotein (a)-apheresis useful?
Bambauer R
Ther Apher Dial; 2005 Apr; 9(2):142-7. PubMed ID: 15828926
[TBL] [Abstract][Full Text] [Related]
38. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis.
Bosch T; Lennertz A; Schenzle D; Dräger J;
J Clin Apher; 2002; 17(4):161-9. PubMed ID: 12494408
[TBL] [Abstract][Full Text] [Related]
39. The current status of therapeutic apheresis devices in the United States.
Siami GA; Siami FS
Int J Artif Organs; 2002 Jun; 25(6):499-502. PubMed ID: 12117288
[TBL] [Abstract][Full Text] [Related]
40. Comparison of double-filtration plasmapheresis (DFPP) versus heparin-mediated extracorporeal LDL-precipitation (HELP)-apheresis in early-onset preeclampsia.
Winkler K; Lorey C; Contini C; Augustinski V; Pütz G; Röthele E; Benner A; Fuchs H; Pecks U; Markfeld-Erol F; Kunze M
Pregnancy Hypertens; 2024 Jun; 36():101128. PubMed ID: 38728925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
